Medis 1 on 1: Martin Sejr-Hansen QFR® and TAVI: A promising development In the interview series ‘Medis 1 on 1’, prof. Hans Reiber interviews a scientist on his/her research in cardiovascular imaging. medisimaging.com/medis-1-on-1-m… #Medis #QFR #imagingsolutions

JAA: In this study, the inter- and intra-observer reproducibility for QFR computed from the same angiograms ranged from high to poor among multiple observers from different sites. ow.ly/gRVU50FTa36

QFR is the future: If you know the volume of an artery using QCA, the time to fill it using the TIMI frame count, and use fluid dynamic modeling, you can calculate the function significance of a lesion without a pressure wire ... for free

Dep. Cardiology, Aarhus University Hospital ranked: 1 in Denmark 2 in the Nordics 31 in the world Good. But we may do better… Department of Cardiology Research AUH Region Midtjylland Aarhus Uni.hospital #cardiotwitter newsweek.com/worlds-best-sp…

800 patients enrolled in FAVOR III trial! Medis would like to congratulate all the involved researchers on reaching this milestone! Learn more on QFR here: lnkd.in/dpxXvkK #Medis #QFR #research #cardiotwitter #imagingsolutions

What a day to remember!! Thanks to Gabor G Toth and Lars Aaberge for a great discussion.

In 1 of 5 the QFR and FFR disagree. Anatomical or physiological factors responsible?Javier Escaned Jelmer Westra Niels R. Holm Ashkan Eftekhari Martin Sejr-Hansen Department of Cardiology Research AUH rdcu.be/cFgtR

Yesterday, prof. Gianluca Campo and his team in Ferrara enrolled patient no 1000 in the The FAVOR III trial. Ferrara is also the top enrolling center followed by Sahlgenska, Sweden and Clinique Axium, Aix-en-Provence, France. Simone Biscaglia Tebaldi Matteo Niels R. Holm

1000 patients enrolled in FAVOR III trial! Medis would like to congratulate all the involved researchers on reaching this milestone! Learn more on QFR here: lnkd.in/dpxXvkK #Medis #QFR #research #cardiotwitter #imagingsolutions

In this study, the inter- and intra-observer reproducibility for quantitative flow ratio computed from the same angiograms ranged from high to poor among multiple observers from different sites. #EAPCI ow.ly/BYv550HZUAR

First price for our OCTOBER Trial PhD student Omeed Neghabat at the Aarhus Universitet 2022 3 min Thesis Competition. Part of the greatest team with Lene Nyhus Andreasen Evald Høj Christiansen Helle Bargsteen and joining Dr Peter O'Kane jcspratt Stuart Watkins FRANCESCO BURZOTTA Simone Biscaglia and more

Check out our paper on visualizing and quantifying the dynamics of CTCF/cohesin loops in living cells which is now online Science Magazine science.org/doi/10.1126/sc… MIT Dept of BE MPI-CBG Dresden Center for Systems Biology Dresden Gene Regulation Observatory Broad Institute MIT Physics

Mød læge og Ph.d.-studerende Omeed Neghabat (Inst. for Klinisk Medicin), som vandt 3 Minute Thesis med præsentationen ”Looking at the human heart from the inside out”. Nu er han med i opløbet for at vinde hovedkonkurrencen, som afgøres d. 10. juni i Padova Coimbra Group Aarhus Uni.hospital

Is QFR non-inferior to FFR? 1200 of 2000 pts included. Hospital Clinico Universitario de Valladolid, Spain, did the milestone case and Sahlgrenska, Sweden leads with 123 cases trailed by 118 in Ferrara, Italy The FAVOR III trial Ignacio J. Amat Javier Escaned Gianluca Campo Simone Biscaglia

Three-Dimensional #Angiographic Characteristics versus Functional Stenosis Severity in Fractional and #Coronary Flow Reserve Discordance: A DEFINE FLOW Sub Study. Valérie Stegehuis Jelmer Westra Martin Sejr-Hansen Niels van Royen Evald Høj Christiansen Tim van de Hoef Nijmegen School of Management Radboud University mdpi.com/2075-4418/12/7…

378 patients to go! Quantitative flow ratio versus fractional flow reserve for guiding percutaneous coronary intervention: design and rationale of the randomised FAVOR III Europe Japan trial via EuroIntervention eurointervention.pcronline.com/article/quanti… Department of Cardiology Research AUH Niels R. Holm Javier Escaned

The FAVOR III Europe Japan randomised trial may determine if QFR-guided coronary artery revascularisation is non-inferior to FFR-guided coronary revascularisation with respect to clinical outcomes. #EAPCI Gianluca Campo ow.ly/2q9B50MspGy

Primary endpoint of the The FAVOR III trial on QFR vs. FFR is presented on 30. October at #TCT2024 #qfr #randomizedtrial #cardiotwitter Birgitte Krogsgaard Evald Høj Christiansen Javier Escaned Gianluca Campo Dr Koltowski Greta Žiubrytė, MD, PhD candidate Martin Sejr-Hansen Ignacio J. Amat Barbara Stähli HernánMR Luigi Di Serafino

Presented today at #TCT2024: Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial hubs.li/Q02W6crZ0 TCT Conference

Proud to be a part of this important work. How will these results impact current guidelines? QFR versus FFR for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial - The Lancet thelancet.com/journals/lance… #CardioTwitter The Lancet